Loading
AMEXHealthcareBiotechnology
Latest quote
$2.695
−$0.015 · -0.55%
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Regular session
$2.695
−$0.015 · -0.55%
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
81
Deep Value
Sentiment
62
Bullish
Risk
41
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Day range
Current $2.695
52-week range
Current $2.695
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 52.74M USD | 53.4M USD | 65.49M USD | 47.64M USD | 38.35M USD |
| Cost of goods sold | 27.51M USD | 24.32M USD | 22.98M USD | 19.59M USD | 16.35M USD |
| Gross profit | 25.24M USD | 29.08M USD | 42.51M USD | 28.05M USD | 22M USD |
| Research and development | 19.05M USD | 12.97M USD | 17.09M USD | 29.35M USD | 29.73M USD |
| Selling, general, and administrative | 11.68M USD | 12.19M USD | 14.96M USD | 11.71M USD | 12.73M USD |
| Operating expenses | 30.74M USD | 25.16M USD | 32.05M USD | 41.06M USD | 42.46M USD |
| Interest income | 1.08M USD | 1.3M USD | 1.29M USD | 1.15M USD | 401K USD |
| Interest expense | 1.19M USD | 1.06M USD | 3.18M USD | 2.53M USD | 7.52M USD |
| Depreciation and amortization | 1.47M USD | 1.3M USD | 1.19M USD | 1.09M USD | 1.12M USD |
| Operating income | −5.5M USD | 3.92M USD | 10.46M USD | −13.01M USD | −20.46M USD |
| Net income | −6.6M USD | 2.93M USD | 8.31M USD | −14.93M USD | −27.58M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
122.63% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 20, 2019 | 1:10 | — | — |
Stock split | Jan 3, 2007 | 1:10 | — | — |
Effective Dec 20, 2019
1:10
Effective Jan 3, 2007
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM5.34M0.01%78.56B USD0.19%$274.91-1.00%
Schwab International Small-Cap Equity ETFSCHC2.45M0.04%5.53B USD0.06%$48.715-1.07%
iShares Russell 2000 Growth ETFIWO2.05M0.01%14.25B USD0.24%$350.54-1.36%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1.97M0.00%41.32B USD0.03%$49.375-1.15%
Vanguard Russell 2000 ETFVTWO1.09M0.01%18B USD0.06%$111.02-1.06%
iShares Micro-Cap ETFIWC687.26K0.05%1.33B USD0.60%$180.87-1.36%
Dimensional - US Small Cap ETFDFAS685.9K0.00%33.66B USD0.31%$77.435-0.62%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM270K0.23%116.75M USD0.73%$15.77-1.25%iShares Russell 2000 ETFIWMSchwab International Small-Cap Equity ETFSCHCiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
